The article from the European Heart Journal discusses recent advances in treatments and biomarkers for heart failure (HF), hypertrophic cardiomyopathy (HCM), and familial hypercholesterolaemia (FH), highlighting both clinical trials and emerging research.
The scientific statement revisits the Open Vein Hypothesis (OVH), which suggests that early clearance of venous thrombus and restoration of blood flow can help prevent postthrombotic syndrome (PTS) following deep vein thrombosis (DVT). PTS is a debilitating condition that affects up to 50% of patients after a DVT and significantly impairs quality of life. The authors note that despite anticoagulation and compression therapy, PTS remains prevalent, highlighting the need for improved prevention strategies.
The study emphasizes the need to adopt an integrated approach to cardiovascular, kidney, and metabolic (CKM) health, which are deeply interconnected and contribute significantly to morbidity and mortality in the U.S. population.
The study assessed patients who underwent cardiac magnetic resonance imaging (CMR) due to reduced left ventricular ejection fraction (LVEF) and a history of atrial or ventricular arrhythmia. AIC was diagnosed retrospectively in patients who showed improvement in LVEF by more than 15% within six months of rhythm control without any other specific heart disease identified. The researchers compared the clinical, laboratory, and imaging characteristics of 86 patients with AIC to those of 463 patients with other non-ischaemic cardiomyopathies (NICM).
The study investigates the role of mitochondrial nicotinamide nucleotide transhydrogenase (NNT) in the development of heart failure with preserved ejection fraction (HFpEF), particularly in the context of cardiometabolic disease. HFpEF is a complex condition lacking effective therapies, and current preclinical models often rely on a “two-hit” approach—combining a high-fat diet with L-NAME (a nitric oxide synthase inhibitor)—to induce HFpEF-like features in mice.
